Physitrack Q2 2023: Initial take - Redeye

Redeye comments on Physitracks’s Q2-results, wherein the reported figures generally align with our estimates. We note stable sales progress and controlled cost escalation, but without notable margin enhancements. Meanwhile, management is confident that the business will be FCF positive by the end of the year. Consequently, we only anticipate minor adjustments to our near-term estimates and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/931758/physitrack-q2-2023-initial-take?utm_source=finwire&utm_medium=RSS